Aplaviroc
From Wikipedia, the free encyclopedia
 |
|
|
Aplaviroc
|
|
| Systematic (IUPAC) name | |
| 4-(4-{[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo- 1,4,9-triazaspiro[5.5]undecan-9-yl]methyl}phenoxy)benzoic acid | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C33H43N3O6 |
| Mol. mass | 577.711 g/mol |
| SMILES | & |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Aplaviroc (INN, codenamed AK602 and GSK-873140) is a novel CCR5 entry inhibitor being developed for the treatment of HIV infection.[1][2]
[edit] References
- ^ http://www.retroconference.org/2004/cd/PDFs/540.pdf
- ^ Potent Anti-R5 Human Immunodeficiency Virus Type 1 Effects of a CCR5 Antagonist, AK602/ONO4128/GW873140, in a Novel Human Peripheral Blood Mononuclear Cell Nonobese Diabetic-SCID, Interleukin-2 Receptor {gamma}-Chain-Knocked-Out AIDS Mouse Model - Nakata et al. 79 (4): 2087 - The Journal of Virology
